BRCA2
Showing 1 - 25 of 861
Breast Cancer, Genetic Disease, BRCA2 Mutation Trial (blood sample for BRCA2 mutation detection)
Not yet recruiting
- Breast Cancer
- +2 more
- blood sample for BRCA2 mutation detection
- (no location specified)
Jun 1, 2023
Germline Variant Carriers With BRCA1 or BRCA2
Recruiting
- BRCA1 and/or BRCA2 Variant Carriers
- +3 more
-
Okayama, JapanOkayama University
Dec 25, 2022
BRCA1/2 Flu Vaccine
Active, not recruiting
- BRCA1 Mutation
- BRCA2 Mutation
- Seasonal influenza vaccine
-
Philadelphia, PennsylvaniaUniversity of Pennsylvania
Aug 16, 2022
BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ovarian Serous Adenocarcinoma Trial in Buffalo, New York (biological, other, drug)
Active, not recruiting
- BRCA1 Gene Mutation
- +5 more
- Durvalumab
- +3 more
-
Buffalo, New York
- +1 more
Jan 20, 2023
BRCA1 Mutation, BRCA2 Mutation, Ovarian Cancer Trial in Providence (Talazoparib Oral Capsule)
Active, not recruiting
- BRCA1 Mutation
- +4 more
- Talazoparib Oral Capsule
-
Providence, Rhode Island
- +1 more
Nov 30, 2022
Metastatic Solid Tumor, BRCA1 Mutation, BRCA2 Mutation Trial in San Francisco (Niraparib, Irinotecan)
Not yet recruiting
- Metastatic Solid Tumor
- +4 more
-
San Francisco, CaliforniaUniversity of California, San Francisco
Jan 12, 2023
Endocrine Disruptors and Life STILe in Breast Cancer Development
Recruiting
- Breast Cancer
- +5 more
-
Roma, ItalyAlessandra Fabi
Feb 25, 2023
Breast Cancer Trial in New York (core needle biopsy, blood draw)
Recruiting
- Breast Cancer
- core needle biopsy
- blood draw
-
New York, New YorkMemorial Sloan Kettering Cancer Center (All Protocol Activities)
Nov 9, 2023
Breast Cancer, Metastatic Breast Cancer, BRCA1 Gene Mutation Trial in Boston (ABT-888, temozolomide)
Active, not recruiting
- Breast Cancer
- +3 more
-
Boston, Massachusetts
- +2 more
Dec 21, 2022
Germline BRCA1 and BRCA2 Mutations in Jewish Women Affected by
Completed
- Breast Cancer
- Blood test
- Questionnaire
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Dec 27, 2021
Triple Negative Breast Tumors, Triple Negative Breast Cancer, Breast Tumors Trial (Pembrolizumab, Paclitaxel, Carboplatin)
Not yet recruiting
- Triple Negative Breast Neoplasms
- +7 more
- Pembrolizumab
- +4 more
- (no location specified)
Aug 1, 2022
Prostate Cancer, BRCA1 Mutation, BRCA2 Mutation Trial (Olaparib, LHRH agonist)
Not yet recruiting
- Prostate Cancer
- +4 more
- Olaparib
- LHRH agonist
- (no location specified)
Aug 10, 2022
Prostate Adenocarcinoma, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8 Trial (Biospecimen Collection,
Not yet recruiting
- Prostate Adenocarcinoma
- +2 more
- Biospecimen Collection
- +6 more
- (no location specified)
Mar 28, 2023
Pancreatic Adenocarcinoma Metastatic, BRCA1 Mutation, BRCA2 Mutation Trial in Boston, New York (Melphalan, BCNU, Vitamin B12B)
Recruiting
- Pancreatic Adenocarcinoma Metastatic
- +14 more
- Melphalan
- +5 more
-
Boston, Massachusetts
- +1 more
Dec 6, 2022
Ultra-rapid BRCA1/2 Status Screening Test in Theranostic
Not yet recruiting
- Breast Cancer
- Questionnaires
- Communication of the results of the BRCA1/2 ultra rapid test
- (no location specified)
Oct 26, 2023
Advanced Breast Cancer, HER2/Neu Negative, Triple-Negative Breast Cancer Trial in Stanford (Talazoparib Tosylate)
Active, not recruiting
- Advanced Breast Cancer
- +2 more
- Talazoparib Tosylate
-
Stanford, CaliforniaStanford University Hospitals and Clinics
Nov 16, 2022
Searching for Novel Germline Mutations in Lobular Breast Cancer
Recruiting
- Lobular Breast Carcinoma
- +3 more
- Illumina panel
-
Milan, ItalyEuropean Institute of Oncology
Sep 12, 2022
BRCA1 Mutation, BRCA2 Mutation Trial in New York, Durham, Houston (Family Letter (Standard of Care), Educational Video, Mailed
Recruiting
- BRCA1 Mutation
- BRCA2 Mutation
- Family Letter (Standard of Care)
- +3 more
-
New York, New York
- +2 more
Aug 12, 2022
l, Laboratory and Epidemiologic Characterization of Individuals
Completed
- Familial Ovarian Cancer
- +3 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Dec 31, 2022
Identification of a Genetic Predisposition to ProstAte Cancer
Active, not recruiting
- Prostate Cancer in BRCA1 and BRCA2 Carriers
- PSA test
- Prostate Biopsy
-
Sutton, Surrey, United KingdomCancer Genetics Unit, Royal Marsden Hospital
Mar 30, 2022
BRCA1/2 Mutation Trial in Philadelphia (INO-5401, INO-9012, Cellectra 2000)
Recruiting
- BRCA1/2 Mutation
- INO-5401
- +2 more
-
Philadelphia, PennsylvaniaUniversity of Pennsylvania
Dec 7, 2021
Molecular Profiling in Prostate Cancer
Recruiting
- Prostate Cancer Metastatic
- +4 more
- Tumor molecular profiling
-
Athens, GreeceHellenic Cooperative Oncology Group
Mar 15, 2022
Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer Trial in United States (Niraparib, Dostarlimab)
Recruiting
- Stage I Breast Cancer
- +7 more
-
Baltimore, Maryland
- +6 more
Nov 11, 2022
TNBC - Triple-Negative Breast Cancer, BRCA1 Mutation, BRCA2 Mutation Trial (olaparib, Durvalumab)
Not yet recruiting
- TNBC - Triple-Negative Breast Cancer
- +2 more
- (no location specified)
Jan 12, 2022
Ovarian Tumors, BRCA1 Protein, BRCA2 Protein Trial in Worldwide (KU-0059436 (AZD2281)(PARP inhibitor))
Active, not recruiting
- Ovarian Neoplasms
- +2 more
- KU-0059436 (AZD2281)(PARP inhibitor)
-
Brussels, Belgium
- +4 more
Dec 19, 2022